Open AccessAstragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease
Author(s) -
Yonghui Hu,
Wangna Tang,
Wenjie Liu,
Zhibo Hu,
Congqing Pan
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s360346
Subject(s) - epithelial–mesenchymal transition , in vivo , mapk/erk pathway , medicine , kidney , cx3cl1 , pharmacology , cancer research , endocrinology , urinary system , chemistry , signal transduction , receptor , chemokine , biology , biochemistry , metastasis , cancer , microbiology and biotechnology , chemokine receptor
Epithelial-mesenchymal transition (EMT) plays an important role in interstitial matrix deposition and renal fibrosis in diabetic kidney disease (DKD). It has been verified that Astragaloside IV (AS-IV) is beneficial for ameliorating DKD. However, the underlying mechanisms of AS-IV on regulating EMT in DKD are yet to be established. Accumulated evidence has suggested that C-X3-C motif ligand 1 (CX3CL1) plays a significant role in the progression of EMT.